Abstract
In this study we examined the effects of the orally active angiotensin-converting enzyme inhibitor SQ 14225 (Captopril) on blood pressure, heart rate, plasma norepinephrine and epinephrine, PRA, aldosterone, cortisol, and serum potassium in 15 sodium-repleted hypertensive patients in the supine position and during 30 min of head-up tilt; in 3 patients the same investigations were repeated after sodium deprivation. On normal sodium intake, a short term treatment with SQ 14225, at average doses of 480 ± 60 mg⁄day, reduced mean supine blood pressure by 19 ± 3 mm Hg (P < 0.001); this change was associated with an increase in PRA of 12.2 ± 3.2 ng⁄ml.h (P < 0.001), a fall in plasma aldosterone of 4.8 ± 1.9 ng⁄100 ml (P < 0.01), and a concurrent rise in serum potassium of 0.26 ±0.1 meq⁄liter (P ⁄ 0.05). Supine heart rate and plasma norepinephrine, epinephrine and cortisol were unchanged. Although in control tilt studies the mean blood pressure was unchanged in all patients, during converting enzyme inhibition (C...
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: The Journal of Clinical Endocrinology & Metabolism
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
